AbbVie Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABBV research report →
Range $275 – $349
Price Chart
About the company
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients.
- CEO
- Robert A. Michael
- IPO
- 2013
- Employees
- 57,000
- HQ
- North Chicago, IL, US
AI snapshot
Six angles, distilled from the data.
ABBV remains in a strong multi-month uptrend and is still trading above its 200-day average of 240.79, with the 50-day at 275.51 confirming a constructive intermediate trend. The stock is also pressing near its 52-week high of 302.93, so the setup favors momentum staying intact unless it loses that elevated range.
Street sentiment is constructive: consensus is Buy, with a 313.8 target versus a 294.67 last close. Recent revisions skew higher, including multiple target raises into the 295-340 range, which signals confidence in execution rather than a fresh downgrade cycle.
AbbVie has a strong beat pattern, going 7 for 8 in the last eight quarters and topping estimates by 2.1% and 0.3% in the two most recent reports. Next-year EPS estimates point sharply higher to 16.1962, so shareholders should watch whether management can sustain that step-up in earnings power.
Recent insider activity leans negative on discretionary signals, led by two open-market sales from the Chief Commercial Officer and a separate sale from the Chief Business/Strategy Officer. Most other entries are awards, exempt exercises, or gifts, which are less informative than the net selling pattern.
Profitability is strong, with a 73.7% gross margin, 36.64% operating margin, and 15.67% net margin. Growth is healthy too, with revenue up 10.3% year over year and earnings up 22.821%, while free cash flow reached $20.244 billion in fiscal 2025.
AbbVie screens as a premium large-cap pharma name, supported by high margins and a 62.25% ROE. The valuation is not cheap versus the sector, but the market is paying for durable cash generation, pipeline breadth, and above-average earnings momentum.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $505.89B
- P/E
- 49.47
- Fwd P/E
- 20.43
- PEG
- 0.15
- P/S
- 7.72
- P/B
- -111.51
- EV/EBITDA
- 23.05
- Div Yield
- 2.40%
- Gross Margin
- 73.72%
- Op Margin
- 32.16%
- Net Margin
- 15.67%
- ROE
- -202.35%
- ROIC
- 15.14%
Latest fiscal year · YoY change
- Revenue
- $61.16B+8.6%
- Gross Profit
- $42.96B+8.9%
- Op Income
- $15.07B
- Net Income
- $4.23B-1.2%
- EPS
- $2.37-1.2%
- OCF Growth
- +1.2%
- FCF Growth
- -0.1%
- 52W High
- $302.93
- 52W Low
- $190.75
- 50D MA
- $278.42
- 200D MA
- $242.12
- Beta
- 0.28
- RSI (14)
- 53
- Avg Volume
- 4.78M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AbbVie beat third-quarter expectations, raised 2026 guidance again, and highlighted a long pipeline of near-term catalysts across immunology, neuroscience, oncology, and aesthetics.· October 30, 2026
- Q3 adjusted EPS was $3.82, beating the midpoint by $0.07; total net revenues were $17.4 billion, up 10.5% operationally.
- Management raised full-year 2026 EPS guidance to $13.95-$13.99 and revenue guidance to about $67.8 billion, with Q4 revenue guided to about $18.4 billion and EPS to $3.83-$3.87.
- Skyrizi and Rinvoq remain the growth engines: Skyrizi sales were nearly $5.8 billion and Rinvoq sales were $2.7 billion, with both still growing strongly despite more competition.
- AbbVie increased its quarterly dividend 5.2% to $1.82 beginning with the February 2027 payment, and said it generated about $14 billion of free cash flow in the first nine months.
- Pipeline momentum was a major theme, with approvals or positive data in Skyrizi Crohn’s subcu induction, Juvmo in Parkinson’s, etentamig in myeloma, and Epkinly in frontline DLBCL.
- Management repeatedly said several assets and franchises are underappreciated by the Street, while also flagging 2027 pricing pressure for Vraylar and continued Imbruvica decline.
AbbVie reported adjusted EPS of $3.82, which was $0.07 above the guidance midpoint. Total net revenues were $17.4 billion, reflecting 10.5% operational growth and a 0.2% unfavorable foreign exchange impact. Adjusted gross margin was 85.1% of sales, adjusted R&D expense was 13.9% of sales, adjusted SG&A expense was 21.2% of sales, and adjusted operating margin was 48.7% of sales. On a product basis, immunology revenue was nearly $9.2 billion, Skyrizi sales were nearly $5.8 billion, Rinvoq sales were $2.7 billion, Humira sales were $683 million, neuroscience revenue was nearly $3.4 billion, Vraylar sales were nearly $1.1 billion, Botox Therapeutic revenues were approximately $1.1 billion, Ubrelvy sales were $449 million, Qulipta sales were $398 million, oncology revenue was $1.7 billion, and aesthetics revenue was nearly $1.2 billion. For full-year 2026, AbbVie raised adjusted EPS guidance to $13.95-$13.99 and raised revenue guidance to approximately $67.8 billion. The company now expects immunology sales of $34.9 billion, including Skyrizi at $21.8 billion and Rinvoq at $10.3 billion; neuroscience sales of $13 billion; oncology sales of $6.6 billion; and aesthetics sales of $5 billion. For Q4, management guided to revenue of about $18.4 billion and adjusted EPS of $3.83-$3.87. AbbVie also said it expects full-year adjusted gross margin above 84% of sales, adjusted R&D of about $9.8 billion, adjusted SG&A of about $14.5 billion, and an adjusted operating margin of about 46.7% of sales. Cash balance at quarter-end was $10.8 billion, and free cash flow was approximately $14 billion in the first nine months of the year.
Rob Michael said AbbVie is performing above expectations and delivered another quarter of “outstanding results,” with top-tier sales and earnings growth plus significant pipeline progress. He emphasized that the company is raising guidance again, increasing the dividend, and building long-term growth drivers that extend into the 2030s through immunology, neuroscience, oncology, and selected business development. His tone was confident and upbeat, while also stressing that AbbVie is focused on differentiated assets and bolt-on deals rather than a large transformational acquisition.
Scott Reents framed the quarter as strong on both growth and profitability, citing adjusted EPS of $3.82, revenue of $17.4 billion, and an 85.1% adjusted gross margin. He noted adjusted R&D at 13.9% of sales, SG&A at 21.2%, and an adjusted operating margin of 48.7%, and said the quarter included an $0.11 unfavorable impact from acquired IPR&D expense. He also detailed capital allocation: $10.8 billion in cash, about $14 billion of free cash flow in the first nine months, a 5.2% dividend increase to $1.82 per share starting with the February 2027 dividend, and a plan to move toward a 2x net leverage ratio over the next 2 to 3 years after closing Apogee.
Analysts focused on what changes could matter for 2027, especially the ramp from Skyrizi’s Crohn’s subcu induction approval, payer access for Rinvoq, and how much of AbbVie’s growth is already baked into models. Management said Skyrizi’s stronger Crohn’s data should accelerate share, but access will still take roughly 60 days or a bit more to fully ramp. On payer dynamics, Jeff Stewart said immunology rebate concessions should remain in the low single-digit range and that access should remain strong across the portfolio. Other questions centered on emraclidine’s prior underdosing, 340B, Botox IRA pricing, the timing of TrenibotE resubmission, and whether AbbVie’s pipeline assets such as etentamig, Epkinly, and 466 are being underappreciated.
The call pointed to several visible growth engines: Skyrizi and Rinvoq are still growing strongly, Skyrizi has a newly approved Crohn’s subcu option, and Rinvoq is moving toward new dermatology indications. AbbVie also has multiple pipeline catalysts in the near term, including Juvmo commercialization, etentamig and Epkinly filings, and additional IBD combination studies, while management expressed confidence that the market is underestimating several assets and franchises.
AbbVie still faces some obvious pressures, including Humira biosimilar erosion, expected Vraylar IRA pricing pressure in 2027, and lower Imbruvica sales due to IRA pricing and share loss. Management also flagged that some launches, like Juvmo, will ramp gradually because broader Medicare coverage is expected later, and that aesthetics remains challenged by economic uncertainty and lower consumer confidence. Several pipeline opportunities remain data-dependent, including Rinvoq in HS, emraclidine, and the timing of further IBD combination readouts.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 1.77B
- Float Shares
- 1.76B
of shares held by institutions
4,369 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ABBV, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Pete SessionsHouse · TX17 | Sell | Sep 14, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | May 5, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Dec 18, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Dec 8, 25 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Jan 24, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Apr 28, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Nov 13, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 180.78M | ▲ 3.03M |
| Blackrock, Inc. | 148.97M | ▼ 513.47K |
| Vanguard Capital Management LLC | 115.68M | ▲ 280.63K |
| State Street Corp | 82.82M | ▲ 218.64K |
| Vanguard Portfolio Management LLC | 49.00M | ▲ 523.34K |
| Geode Capital Management, LLC | 47.50M | ▲ 505.34K |
| Jpmorgan Chase & Co | 45.33M | ▼ 2.53M |
| Morgan Stanley | 38.40M | ▼ 502.27K |
| Capital Research Global Investors | 31.12M | ▲ 1.01M |
| Norges Bank | 25.55M | ▲ 25.55M |
| Bank Of America Corp | 21.24M | ▼ 2.70M |
| Capital World Investors | 20.65M | ▲ 1.47M |
Held by 3,036 ETFs
Biggest fund positions in ABBV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | SALEKI AZITA | other | 23,935 |
| Nov 16, 26 | SALEKI AZITA | other | 13,481 |
| Nov 16, 26 | SALEKI AZITA | other | 13,481 |
| Nov 9, 26 | Stewart Jeffrey Ryan | other | 24,549 |
| Nov 9, 26 | Stewart Jeffrey Ryan | other | 16,070 |
| Nov 9, 26 | Stewart Jeffrey Ryan | sell | 40,619 |
| Nov 12, 26 | Stewart Jeffrey Ryan | other | 3,450 |
| Nov 9, 26 | Stewart Jeffrey Ryan | other | 24,549 |
| Nov 9, 26 | Stewart Jeffrey Ryan | other | 16,070 |
| Oct 14, 26 | Carethers John | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABBV coverage
Recent articles, reports, and earnings notes.

AbbVie (ABBV): Growth Momentum vs. Valuation Risk
AbbVie is delivering strong growth from Skyrizi, Rinvoq and neuroscience, but a rich valuation and heavy debt keep the stock in Hold territory.

TriGemX Bio SPAC Merger: Late-Stage Migraine Bet Meets Cash Risk
TriGemX Bio is a clinical-stage biotech developing elismetrep for acute migraine, and it is going public through a merger with TCGX Acquisition Corp. The deal is expected to close in the first quarter of 2027, but the setup still hinges on redemptions, dilution, and whether Phase 3 execution stays on track.

AbbVie (ABBV): Skyrizi and Rinvoq Drive the Transition
AbbVie is successfully replacing Humira with fast-growing immunology and neuroscience assets, supporting a Buy view despite heavy debt and a rich valuation. Skyrizi, Rinvoq, and neuroscience growth are offsetting legacy erosion and keeping earnings momentum intact.
Want a deeper read on ABBV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
247wallst.com · Nov 20
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 20
AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
prnewswire.com · Nov 20
Advisors Asset Management Inc. Buys New Shares in AbbVie Inc. $ABBV
defenseworld.net · Nov 20
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
marketwatch.com · Nov 18
Invest $100,000 in These 4 Dividend Stocks and Collect Passive Income for Life
247wallst.com · Nov 18
AbbVie Inc. $ABBV Holdings Cut by Bridges Investment Management Inc.
defenseworld.net · Nov 18
How Did AbbVie's Neuroscience Franchise Perform in Q3?
zacks.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice